Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Global X Genomics & Biotechnology ETF(GNOM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GNOM
10/28/2026: GNOM (2-star) is currently NOT-A-BUY. Pass it for now.
The Global X Genomics & Biotechnology ETF (GNOM) provides targeted exposure to companies involved in gene editing and genomic sequencing through a rules-based index strategy. It offers a transparent, lower-cost alternative to active thematic funds, making it an efficient tool for thematic allocation. While it benefits from the high growth potential of the healthcare innovation sector, investors should be aware of the inherent concentration, regulatory, and high-volatility risks associated with biotech. The fund is best suited for growth-oriented investors looking to capture long-term technological trends, rather than those seeking core stability or immediate income.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund focuses on innovative biotechnology companies that rely on high growth expectations. |
| Momentum investor | Mixed fit | This fund is a fit for momentum strategies when the biotech sector is experiencing a positive upswing and strong clinical catalysts. |
| Value investor | Weak fit | Most holdings in the genomics sector are pre-revenue or early-stage, making them less suitable for traditional value-based metrics. |
| Dividend/Income investor | Weak fit | Genomics companies typically reinvest all cash flow into R&D and rarely pay dividends. |
| Low-risk investor | Weak fit | The high volatility and clinical-trial risk inherent in genomics make this unsuitable for low-risk portfolios. |
Investor Profile
Ideal Investor Profile
The ideal investor is an aggressive growth-oriented participant willing to tolerate high volatility in exchange for potential long-term exposure to biotech innovation.
Suitability
GNOM is best suited for long-term investors seeking a thematic satellite position in their portfolio rather than core index followers.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Biotech stocks are prone to sharp price swings based on clinical study outcomes. |
| Market risk | High | The fund is highly sensitive to broad market sentiment toward high-growth technology and healthcare stocks. |
| Concentration | High | By focusing on a single niche (genomics), the fund lacks diversification across other sectors. |
| Tracking/expense | Low | The passive structure ensures the expense ratio remains stable and predictable. |
| Liquidity | Medium | Some smaller-cap holdings may experience liquidity constraints during periods of market stress. |
| Business/sector quality | Medium / high | Regulatory and scientific risk is significant, as company viability depends on technological success. |
Risk Analysis
Volatility
GNOM exhibits higher-than-average beta, making it significantly more volatile than the broader S&P 500 index.
Market Risk
The fund is exposed to systemic risks, particularly interest rate sensitivity and the cyclical nature of clinical healthcare innovation.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Genomics & Genetic Engineering Companies | 98 | This provides concentrated exposure to the innovative biotechnology firms driving the genetic sequencing and editing market. |
| Cash/collateral | Cash and Cash Equivalents | 2 | This represents residual cash held for operational purposes and liquidity management. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 70.36% | Avg. Invested days 87 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.